BYLVAY DIN 02542641
Status: Marketed
Holder: MEDISON PHARMA CANADA INC.
Health Canada record
| Active ingredient(s) | ODEVIXIBAT 200 MCG |
|---|
| Dosage form | Capsule |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | A05AX05 ODEVIXIBAT |
|---|
| Original market date | 07-Feb-2024 |
|---|
| Current status date | 07-Feb-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Medison Pharma Canada Inc. — licence 3-002662, currently licensed, last inspection rating C (2026-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ODEVIXIBAT
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02542676 | BYLVAY | MEDISON PHARMA CANADA INC. | Capsule | ODEVIXIBAT 400 MCG | Marketed |
| 02542684 | BYLVAY | MEDISON PHARMA CANADA INC. | Capsule | ODEVIXIBAT 600 MCG | Marketed |
| 02542692 | BYLVAY | MEDISON PHARMA CANADA INC. | Capsule | ODEVIXIBAT 1200 MCG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 31966 | 2023-10-30 | New Drug Submission (NDS) | |
Request a quote for BYLVAY
How to read a Canadian DIN record